ATE394122T1 - Hemmung des cd95 liganden/rezeptor-systems zur behandlung von neurologischen erkrankungen und verletzungen - Google Patents
Hemmung des cd95 liganden/rezeptor-systems zur behandlung von neurologischen erkrankungen und verletzungenInfo
- Publication number
- ATE394122T1 ATE394122T1 AT04709605T AT04709605T ATE394122T1 AT E394122 T1 ATE394122 T1 AT E394122T1 AT 04709605 T AT04709605 T AT 04709605T AT 04709605 T AT04709605 T AT 04709605T AT E394122 T1 ATE394122 T1 AT E394122T1
- Authority
- AT
- Austria
- Prior art keywords
- treatment
- injuries
- ligand
- inhibition
- receptor system
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03003426A EP1447093A1 (de) | 2003-02-14 | 2003-02-14 | Inhibition des CD95 Ligand/Rezeptorsystems zur Behandlung neurologischer Störungen und Verletzungen |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE394122T1 true ATE394122T1 (de) | 2008-05-15 |
Family
ID=32668981
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT04709605T ATE394122T1 (de) | 2003-02-14 | 2004-02-10 | Hemmung des cd95 liganden/rezeptor-systems zur behandlung von neurologischen erkrankungen und verletzungen |
Country Status (10)
Country | Link |
---|---|
US (1) | US7935339B2 (de) |
EP (2) | EP1447093A1 (de) |
JP (1) | JP4800920B2 (de) |
AT (1) | ATE394122T1 (de) |
AU (1) | AU2004212308C1 (de) |
CA (1) | CA2514794C (de) |
DE (1) | DE602004013540D1 (de) |
DK (1) | DK1592446T3 (de) |
ES (1) | ES2301966T3 (de) |
WO (1) | WO2004071528A1 (de) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR064501A1 (es) | 2006-12-22 | 2009-04-08 | Genentech Inc | Antagonistas del dr6 (receptor de muerte 6) y usos de los mismos en el tratamiento de trastornos neurologicos |
PT2428252E (pt) | 2006-12-28 | 2014-12-11 | Universitätsklinikum Heidelberg | Neutralização de atividade de blocos de invasão cd95 de células de glioblastoma in vivo |
JP5665739B2 (ja) * | 2008-07-14 | 2015-02-04 | ドイチェス クレープスフォルシュングスツェントルムDeutsches Krebsforschungszentrum | 炎症性疾患を治療するためのcd95インヒビターの使用 |
EA201190025A1 (ru) | 2008-11-25 | 2012-12-28 | Байоджен Айдек Ма Инк. | ПРИМЕНЕНИЕ АНТАГОНИСТОВ DR6 И p75 ДЛЯ ПРОМОТИРОВАНИЯ ВЫЖИВАНИЯ КЛЕТОК НЕРВНОЙ СИСТЕМЫ |
AR078986A1 (es) | 2009-11-12 | 2011-12-14 | Genentech Inc | Un metodo para promover la densidad de espinas dendriticas |
MA45488A (fr) | 2015-10-22 | 2018-08-29 | Juno Therapeutics Gmbh | Procédés, kits et appareil de culture de cellules |
CN111546719B (zh) * | 2020-04-21 | 2022-07-01 | 中国船舶重工集团公司第七二五研究所 | 一种磁性宽频带电磁吸波超材料 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4447484C2 (de) * | 1994-04-08 | 1997-07-17 | Deutsches Krebsforsch | Mittel zur Hemmung von Apoptose |
CN1196733A (zh) | 1995-06-30 | 1998-10-21 | 持田制药株式会社 | 抗Fas配体抗体和利用抗Fas配体抗体的测定方法 |
EP0992243B1 (de) | 1996-10-31 | 2004-08-18 | Mochida Pharmaceutical Co., Ltd. | Fas-Antagonist FÜR DIE PROPHYLAXE ODER THERAPIE VON GVHD |
US6001962A (en) * | 1996-11-15 | 1999-12-14 | The Regents Of The University Of California | Modified Fas ligands |
ATE393222T1 (de) | 1997-09-18 | 2008-05-15 | Genentech Inc | Dcr3 polypeptid, ein tnfr homolog |
JP4590504B2 (ja) * | 1999-03-30 | 2010-12-01 | イーライ リリー アンド カンパニー | プロテアーゼ耐性flint類似体 |
US6463591B1 (en) * | 1999-05-26 | 2002-10-15 | Ikuo Toratani | Clothing such as shorts and bathing suit |
DE19959049A1 (de) * | 1999-12-07 | 2001-06-28 | Deutsches Krebsforsch | Kombination von Verbindungen, welche die biologischen Wirkungen von TNF-alpha und CD95L hemmen |
AR027993A1 (es) | 2000-03-29 | 2003-04-23 | Vertex Pharma | Inhibidores de carbonato de caspasa y usos del mismo |
US7115717B2 (en) * | 2001-05-18 | 2006-10-03 | Kirin Beer Kabushiki Kaisha | Anti-TRAIL-R antibodies |
-
2003
- 2003-02-14 EP EP03003426A patent/EP1447093A1/de not_active Withdrawn
-
2004
- 2004-02-10 WO PCT/EP2004/001233 patent/WO2004071528A1/en active IP Right Grant
- 2004-02-10 AU AU2004212308A patent/AU2004212308C1/en not_active Ceased
- 2004-02-10 DK DK04709605T patent/DK1592446T3/da active
- 2004-02-10 ES ES04709605T patent/ES2301966T3/es not_active Expired - Lifetime
- 2004-02-10 US US10/545,231 patent/US7935339B2/en not_active Expired - Fee Related
- 2004-02-10 JP JP2006501795A patent/JP4800920B2/ja not_active Expired - Fee Related
- 2004-02-10 DE DE602004013540T patent/DE602004013540D1/de not_active Expired - Lifetime
- 2004-02-10 CA CA2514794A patent/CA2514794C/en not_active Expired - Fee Related
- 2004-02-10 EP EP04709605A patent/EP1592446B1/de not_active Expired - Lifetime
- 2004-02-10 AT AT04709605T patent/ATE394122T1/de not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
AU2004212308C1 (en) | 2009-10-29 |
US7935339B2 (en) | 2011-05-03 |
AU2004212308B2 (en) | 2009-05-21 |
AU2004212308A1 (en) | 2004-08-26 |
CA2514794A1 (en) | 2004-08-26 |
ES2301966T3 (es) | 2008-07-01 |
DE602004013540D1 (de) | 2008-06-19 |
DK1592446T3 (da) | 2008-09-01 |
CA2514794C (en) | 2013-05-28 |
JP4800920B2 (ja) | 2011-10-26 |
EP1447093A1 (de) | 2004-08-18 |
JP2006517559A (ja) | 2006-07-27 |
WO2004071528A1 (en) | 2004-08-26 |
EP1592446B1 (de) | 2008-05-07 |
EP1592446A1 (de) | 2005-11-09 |
US20060234968A1 (en) | 2006-10-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE427759T1 (de) | Behandlung von fettsucht und verbundenen erkrankungen | |
ATE445415T1 (de) | Verwendung von il-23 und il-17-antagonisten zur behandlung von autoimmuner entzündlicher augenerkrankung | |
DE602004020072D1 (de) | 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen | |
ATE456955T1 (de) | Verwendung von cyclodextrin zur behandlung und vorbeugung von entzündlichen bronchialerkrankungen | |
ATE554756T1 (de) | Kombination aus epothilon-analog und chemotherapeutika zur behandlung von proliferativen erkrankungen | |
ATE440866T1 (de) | Nogo-a-neutralisierende immunglobuline zur behandlung neurologischer krankheiten | |
ATE415968T1 (de) | 3,11b-cis-dihydrotetrabanezin zur behandlung von schizophrenie und anderen psychosen | |
ATE376828T1 (de) | Verwendung von rotigotin zur behandlung und prävention des parkinson-plus-syndroms | |
EP1809369A4 (de) | Medizinprodukte für nachweis, prävention und/oder behandlung von neurologischen erkrankungen und relevante verfahren | |
EP1885398A4 (de) | Hemmung des alternativen komplementweges zur behandlung traumatischer gehirnverletzungen, rückenmarksverletzungen und verwandter leiden | |
DE60216139D1 (de) | Arylharnstoff-verbindungen in kombination mit anderen zytostatisch oder zytotoxisch wirksamen stoffen zur behandlungen menschlicher krebserkrankungen | |
IL219857A0 (en) | Mitotic kinesin inhibitors, pharmaceutical compositions comprising them, uses thereof in the manufacture of a medicament for the treatment of disease or disorder in a human or animal that can be treated by inhibiting mitosis | |
ATE286028T1 (de) | Aminopyrazolderivate zur behandlung von übergewicht und anderen gesundheitsstörungen | |
ATE446754T1 (de) | Verbindungen zur behandlung von schizophrenie und/oder glucoregulatorische auffälligkeiten | |
ATE369133T1 (de) | Zur behandlung von schmerzen geeignete therapeutische mittel | |
ATE494890T1 (de) | Alpha-aminoamid-derivate zur behandlung von suchtstörungen | |
NO20054913D0 (no) | Anvendelse av clustein for behandling og/eller forebyggelse av perifere nevrologiske lidelser | |
ATE555803T1 (de) | Verwendung von osteopontin zur behandlung und/oder vorbeugung von neurologischen erkrankungen | |
NO20055563L (no) | Midler for behandlingen av lavere abdominale lidelser | |
TW200505904A (en) | Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands | |
TW200735868A (en) | Compositions and methods for treating CNS disorders | |
DE502004010131D1 (de) | Pyridopyrimidinone zur behandlung von krebserkrankungen | |
DE50109156D1 (de) | Mittel zur behandlung von erkrankungen des tracheo-bronchialtraktes, insbesondere der copd | |
ATE422498T1 (de) | Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems | |
ATE420071T1 (de) | 2- (1h-indolylsulfanyl) -arylaminderivate zur verwendung bei der behandlung von affektiven psychosen, schmerzen, dem hyperkinetischen syndrom des kindesalters (adhd) und stressharninkontinenz |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1592446 Country of ref document: EP |
|
REN | Ceased due to non-payment of the annual fee |